BTIG analyst Mark Massaro maintained a Buy rating on Cue Health (HLTH – Research Report) yesterday and set a price target of $2.00. The company’s shares closed last Friday at $0.16.
Massaro covers the Healthcare sector, focusing on stocks such as Guardant Health, Personalis, and SOPHiA GENETICS. According to TipRanks, Massaro has an average return of -15.6% and a 33.00% success rate on recommended stocks.
Cue Health has an analyst consensus of Moderate Buy, with a price target consensus of $1.33.
See the top stocks recommended by analysts >>
The company has a one-year high of $2.82 and a one-year low of $0.16. Currently, Cue Health has an average volume of 450.6K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cue Health (HLTH) Company Description:
Cue Health Inc is a health technology company. It puts consumers in control of health information and places diagnostic information at the center of care. It enables people to manage health through real-time, actionable and connected health data. Further, it offers individuals, enterprises, government agencies and healthcare providers access to lab-quality diagnostic testing at home, at work, or at the point-of-care, all in a device that fits in the palm of hand.
Read More on HLTH:
